LY2886721

DRUG6 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy Volunteers

Phase 1

A Safety Study of LY2886721 Single Doses in Healthy Subjects

CompletedNCT01133405

Eli Lilly and CompanyAlzheimer's Disease

Start: 2010-06-30End: 2010-10-31Updated: 2019-09-16

A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

CompletedNCT01227252

Eli Lilly and CompanyAlzheimer's Disease

Start: 2010-12-31End: 2011-04-30Updated: 2019-07-19

Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants

CompletedNCT01367262

Eli Lilly and CompanyHealthy Volunteers

Start: 2011-06-30End: 2011-07-31Updated: 2019-09-13

A Study of LY2886721 in Healthy Participants

CompletedNCT01534273

Eli Lilly and CompanyHealthy Volunteers

Start: 2012-02-29End: 2012-07-31Updated: 2019-08-28

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

TerminatedNCT01561430

Eli Lilly and CompanyAlzheimer's Disease

Start: 2012-03-31End: 2013-08-31Updated: 2018-05-18

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

CompletedNCT01807026

Eli Lilly and CompanyAlzheimer Disease, Healthy Volunteers

Start: 2013-03-31End: 2013-05-31Updated: 2019-07-19